From 9th February 2019 will be active the new Delegated Regulation (UE) 2016/161, that provides for an obligation of a unique identifier in order to verify the medicinal authenticity and to identify the individual packs.
Also in the pharma sector there is the necessity to customize the products and to reduce the lots. The drugs are switching from the “one drug fits all” to the “drug custom” concept.
For this reason the companies are very interesting to the National Industry 4.0 Plan and to its investment opportunities; it could offer a technology evolution that allows them to respect the regulations’ requirements.
In this new Regulation 2016/161 the final goal is try to fight counterfeiting of drugs: the drugs should have an unique identification code.
In order to allow this practice to take place, the methodology “Track and Trace” must be adopted, which will allow to identify each single grouping of packages.